PDA-001: Phase IIa started

Celgene disclosed in its 3Q10 earnings that it began a double-blind, placebo-controlled, U.S. Phase IIa trial to evaluate 1, 4 or 8 units of IV PDA-001 on days 0 and 7 in 52 patients. ...